Radionuclide Therapy for Osseous Metastases in Prostate Cancer
Bone metastases are associated with increased morbidity and poor prognosis in castration-resistant prostate cancer. Since 2010, 5 systemic therapies for metastatic castration-resistant prostate cancer have been approved by the US Food and Drug Administration based on an improvement in overall survival, offering alternatives to docetaxel, a chemotherapeutic agent with modest effect and significant toxicity. These systemic treatments belong to different classes of medication such as immunotherapy, hormonal therapy, chemotherapy, and radionuclide therapy.
Source: Seminars in Nuclear Medicine - Category: Radiology Authors: Alain S. Abi-Ghanem, Mary A. McGrath, Heather A. Jacene Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Food and Drug Administration (FDA) | Hormonal Therapy | Hormones | Prostate Cancer | Radiology | Taxotere | Toxicology